Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Gemcitabine With or Without Bevacizumab in Pancreatic Cancer
NCT00253526Phase 2Withdrawn
- Sponsor
- National Cancer Institute
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, randomised, open-label trial of bevacizumab in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by National Cancer Institute. Primary endpoint: Disease-free interval. Status: withdrawn.
02
Drugs
bevacizumab
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT00253526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00253526.